Eloxx Pharmaceuticals stock: CEO to present at healthcare conference

Eloxx Pharmaceuticals will present at the 3rd Annual Guggenheim Healthcare Innovation Conference from November 9 to 11, 2026, the company said in a release carried by Morningstar.

Chief Executive Officer Sumit Aggarwal is scheduled to speak on Monday, November 9, from 11:30 to 11:55 a.m. Eastern Time. A live webcast is planned through the company's investor website, with a replay to follow.

Clinical pipeline remains central

Eloxx is a clinical-stage biotechnology company developing small-molecule candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. Its lead candidate, exaluren, is being developed for rare kidney diseases including nonsense-mutation Alport syndrome and autosomal dominant polycystic kidney disease.

The conference appearance gives investors a scheduled opportunity to hear management discuss development plans and the broader pipeline. The company also has an agreement with Almirall covering ZKN-013, which is being developed for rare dermatological diseases associated with nonsense mutations.

Company profile

Eloxx Pharmaceuticals is headquartered in Watertown, Massachusetts, and trades on the Nasdaq Capital Market under the symbol ELOX. Its business is focused on clinical-stage therapies for rare and ultra-rare genetic diseases, with exaluren as its lead program and additional discovery projects in earlier development. The company therefore occupies a specialized position within biotechnology, centered on mutation-driven diseases rather than a broad commercial drug portfolio.

Eloxx Pharmaceuticals at a glance

• Company: Eloxx Pharmaceuticals, Inc.
• Ticker: ELOX
• Sector: Healthcare
• Industry: Biotechnology
• Headquarters: Watertown, Massachusetts, United States
• Chief executive: Sumit Aggarwal